Institution · Forma Therapeutics (United States)

Most cited papers from Forma Therapeutics (United States)

Forma Therapeutics (United States)

What are the most cited papers from Forma Therapeutics (United States)?

The most cited paper from Forma Therapeutics (United States) is "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors" (Adeela Kamal, Lia Thao, John Sensintaffar et al., 2003), with 1,396 citations. Next come "Molecular basis of USP7 inhibition by selective small-molecule inhibitors" (483) and "BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition" (432).

Published TypeFieldAccessCitations

Showing 50 of 62 papers. Every paper with more than 31 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Adeela Kamal, Lia Thao, John Sensintaffar et al. · Nature	Sep 2003	1,396
2	Molecular basis of USP7 inhibition by selective small-molecule inhibitors A.P. Turnbull et al. · Nature Open access	Oct 2017	483
3	BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition Marco H. Hofmann et al. · Cancer Discovery Open access	19 Aug 2020	432
4	Targeting multiple signal transduction pathways through inhibition of Hsp90 Hong Zhang, Francis J. Burrows · Journal of Molecular Medicine	26 May 2004	375
5	HIF‐dependent induction of adenosine A2B receptor in hypoxia Tianqing Kong, Karen A. Westerman, Marion Faigle et al. · The FASEB Journal	31 Oct 2006	335
6	Therapeutic and diagnostic implications of Hsp90 activation Adeela Kamal, Marcus F. Boehm, Francis J. Burrows · Trends in Molecular Medicine ReviewOpen access	13 May 2004	280
7	Influenza Infection Leads to Increased Susceptibility to Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the Lung Cherrie-Lee N. Small, Christopher R. Shaler, Sarah M. McCormick et al. · The Journal of Immunology Open access	18 Jan 2010	224
8	Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6 Nina Kerres et al. · Cell Reports Open access	Sep 2017	209
9	Hsp90 Activation and Cell Cycle Regulation Francis J. Burrows, Hong Zhang, Adeela Kamal · Cell Cycle Open access	Dec 2004	161
10	HSP induction mediates selective clearance of tau phosphorylated at proline‐directed Ser/Thr sites but not KXGS (MARK) sites Chad A. Dickey, Judith Dunmore, Bingwei Lu et al. · The FASEB Journal	7 Feb 2006	159
11	Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor Justin A. Caravella, Jian Lin, R. Bruce Diebold et al. · Journal of Medicinal Chemistry Open access	23 Jan 2020	151
12	USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation Emma V. Rusilowicz-Jones et al. · Life Science Alliance Open access	7 Jul 2020	137
13	Principles of cargo attachment to cytoplasmic motor proteins Adeela Kamal, Lawrence S.B. Goldstein · Current Opinion in Cell Biology Review	Feb 2002	136
14	Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML Stéphane de Botton et al. · Blood Advances Open access	Feb 2023	133
15	Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial Justin M. Watts et al. · The Lancet Haematology Open access	9 Nov 2022	121
16	ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia Januario E. Castro, Carlos Enrique Prada, Olivier J. Loria et al. · Blood Open access	22 Jun 2005	121
17	7‘-Substituted Benzothiazolothio- and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors Lin Zhang, Junhua Fan, K. NGUYEN VU et al. · Journal of Medicinal Chemistry Open access	28 Jul 2006	115
18	Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2 Namrata Bora-Singhal, Durairaj Mohankumar, Biswarup Saha et al. · Scientific Reports Open access	13 Mar 2020	94
19	Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics Julie E. Button, Chloe A. Autran, Abigail L. Reens et al. · Cell Host & Microbe Open access	May 2022	89
20	Quantitative Comparison of Enrichment from DNA-Encoded Chemical Library Selections John C. Faver, Kevin P. Riehle, David R. Lancia et al. · ACS Combinatorial Science Open access	23 Jan 2019	89
21	Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State Martin Kurnik, Cagla Sahin, Camilla Bertel Andersen et al. · Cell chemical biology Open access	6 Sep 2018	88
22	The heat‐shock protein 90 inhibitor 17‐allylamino‐17‐demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis Cinzia Dello Russo, Paul E. Polak, Pilar R. Mercado et al. · Journal of Neurochemistry	19 Sep 2006	86
23	Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90 Jean‐Yves Le Brazidec, Adeela Kamal, David J. Busch et al. · Journal of Medicinal Chemistry Open access	17 Jun 2004	84
24	Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors Xiaozhang Zheng et al. · Journal of Medicinal Chemistry Open access	16 Jul 2013	83
25	Distinct USP25 and USP28 Oligomerization States Regulate Deubiquitinating Activity Malte Gersch, Jane L. Wagstaff, Angela V. Toms et al. · Molecular Cell Open access	26 Mar 2019	79
26	Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial Macarena I. de la Fuente, Howard Colman, Mark Andrew Rosenthal et al. · Neuro-Oncology Open access	25 May 2022	77
27	Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor Neil T. Burford, Kathryn E. Livingston, Meritxell Canals et al. · Journal of Medicinal Chemistry Open access	22 Apr 2015	76
28	Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors Xiaozhang Zheng et al. · Journal of Medicinal Chemistry Open access	25 Apr 2013	76
29	Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90 Marco A. Biamonte, Jiandong Shi, Kevin Hong et al. · Journal of Medicinal Chemistry Open access	24 Dec 2005	73
30	Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11 Matthew W. Martin, Jennifer Y. Lee, David R. Lancia et al. · Bioorganic & Medicinal Chemistry Letters Open access	9 May 2018	67
31	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms Lanzhu Yue et al. · Blood Open access	21 Nov 2019	66
32	One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS Jürgen Ramharter et al. · Journal of Medicinal Chemistry Open access	15 Mar 2021	65
33	Multiple Sclerosis Performance Test: Technical Development and Usability Jane Rhodes, David Schindler, Stephen M. Rao et al. · Advances in Therapy Open access	3 May 2019	64
34	Efficient APC/C substrate degradation in cells undergoing mitotic exit depends on K11 ubiquitin linkages Mingwei Min, Tycho E.T. Mevissen, Maria De Luca et al. · Molecular Biology of the Cell Open access	7 Oct 2015	61
35	Identification of new biomarkers for clinical trials of Hsp90 inhibitors Hong Zhang, Daun Chung, Yong‐Ching Yang et al. · Molecular Cancer Therapeutics	May 2006	61
36	Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials Carine Beysen, Patricia E. Schroeder, Eric L. Wu et al. · Diabetes Obesity and Metabolism Open access	2 Dec 2020	55
37	USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma E Josue Ruiz et al. · eLife Open access	11 Oct 2021	52
38	Multiple Sclerosis Performance Test: validation of self‐administered neuroperformance modules Stephen M. Rao, Rachel Galioto, Mark J. Sokolowski et al. · European Journal of Neurology	3 Feb 2020	52
39	Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors Jian Lin et al. · Journal of Medicinal Chemistry Open access	14 Jun 2019	49
40	Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase Angela Jinsook Oh, Yen‐Ching Ho, Mark Zak et al. · ChemBioChem Open access	5 May 2014	48
41	Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease Patricia E. Schroeder, Keertik S. Fulzele, Sanjeev Forsyth et al. · Journal of Pharmacology and Experimental Therapeutics Open access	15 Jan 2022	47
42	Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT) Xiaozhang Zheng et al. · Bioorganic & Medicinal Chemistry Letters Open access	22 Aug 2013	46
43	The deubiquitylase USP9X controls ribosomal stalling Anne Clancy et al. · The Journal of Cell Biology Open access	12 Dec 2020	45
44	Structural and Functional Insights into Human Nuclear Cyclophilins Caroline Rajiv, Tara L. Davis · Biomolecules Open access	4 Dec 2018	45
45	Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents Andrew D.J. Pearson et al. · European Journal of Cancer Open access	17 Jul 2020	44
46	Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT) Anthony M. Giannetti et al. · Journal of Medicinal Chemistry Open access	9 Jan 2014	42
47	Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties Janet Gunzner-Toste et al. · Bioorganic & Medicinal Chemistry Letters Open access	25 Apr 2013	42
48	Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors Mark Zak, Po‐wai Yuen, Xiongcai Liu et al. · Journal of Medicinal Chemistry Open access	19 Aug 2016	40
49	Synthesis of Multifunctional 2-Aminobenzimidazoles on DNA via Iodine-Promoted Cyclization Liqiang Su, Jing Feng, Ting Peng et al. · Organic Letters	30 Jan 2020	39
50	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors Weiru Wang, Kristi Elkins, Angela Jinsook Oh et al. · PLoS ONE Open access	6 Oct 2014	39

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.